Teva Pharmaceutical Industries

NYSE:TEVA Stock Report

Mkt Cap: US$9.6b

Teva Pharmaceutical Industries Financial Health

How is Teva Pharmaceutical Industries's financial position?

[object Object] Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TEVA's short term assets ($11.5B) do not cover its short term liabilities ($11.5B).

Long Term Liabilities: TEVA's short term assets ($11.5B) do not cover its long term liabilities ($23.2B).


Debt to Equity History and Analysis

Debt Level: TEVA's net debt to equity ratio (200.1%) is considered high.

Reducing Debt: TEVA's debt to equity ratio has increased from 114.9% to 223.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable TEVA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: TEVA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 44.2% per year.


Discover healthy companies